 Hand eczema is one of the most common skin diseases, affecting approximately 8 million Americans, and currently there are no FDA-approved therapies for this affliction, said Howard Welgus, M.D., Arcutis Chief Medical Officer. The Phase 1 portion of the study will assess the safety, tolerability and pharmacokinetics of once daily application of ARQ-252 cream 0.3 to both hands for two weeks in six subjects with chronic hand eczema. 